GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Han Biomedical Inc (ROCO:6999) » Definitions » EBIT

Han Biomedical (ROCO:6999) EBIT : NT$31.2 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Han Biomedical EBIT?

Han Biomedical's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was NT$13.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$31.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Han Biomedical's annualized ROC % for the quarter that ended in Jun. 2024 was 37.57%. Han Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 63.48%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Han Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 4.96%.


Han Biomedical EBIT Historical Data

The historical data trend for Han Biomedical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Han Biomedical EBIT Chart

Han Biomedical Annual Data
Trend Dec21 Dec22 Dec23
EBIT
16.70 24.42 27.27

Han Biomedical Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24
EBIT - - 9.24 18.02 13.16

Competitive Comparison of Han Biomedical's EBIT

For the Biotechnology subindustry, Han Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Han Biomedical's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Han Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Han Biomedical's EV-to-EBIT falls into.


;
;

Han Biomedical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$31.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Han Biomedical  (ROCO:6999) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Han Biomedical's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=22.628 * ( 1 - 20.62% )/( (53.783 + 41.826)/ 2 )
=17.9621064/47.8045
=37.57 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=229.503 - 16.089 - ( 159.631 - max(0, 20.812 - 211.909+159.631))
=53.783

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=269.052 - 30.315 - ( 196.911 - max(0, 32.838 - 257.203+196.911))
=41.826

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Han Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=26.314/( ( (16.223 + max(32.347, 0)) + (10.466 + max(23.868, 0)) )/ 2 )
=26.314/( ( 48.57 + 34.334 )/ 2 )
=26.314/41.452
=63.48 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(32.509 + 16.267 + 0.13799999999998) - (16.089 + 0 + 0.478)
=32.347

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(28.042 + 25.478 + 0.86099999999999) - (30.315 + 0 + 0.198)
=23.868

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Han Biomedical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=31.18/629.111
=4.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Han Biomedical EBIT Related Terms

Thank you for viewing the detailed overview of Han Biomedical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Han Biomedical Business Description

Traded in Other Exchanges
N/A
Address
Xintai 5th Road, 15F-11, No.99, Sec.1, Xizhi District, New Taipei City, TWN
Han Biomedical Inc operates as a bio-material technology platform for the tissue repair market.

Han Biomedical Headlines

No Headlines